Search Contact Legal Statement
Index Sitemap link to Roche Diagnostics Global
About us Health Information News Related links Contact us Careers
UK Press Releases

Group Press Releases

Archived Press Releases
border=Fourth Roche Continents study week for 100 students
For the fourth time, Roche and the Salzburg Festival have invited 100 students to take part in Roche Continents. Science, music and art students from 43 different countries will be spending a week together in Salzburg discussing creativity in their respective fields of study and uncovering the common ground in what at first glance appear to be very different disciplines.
border=Roche posts good half year results
Operating profit increases significantly faster than sales – double-digit growth for Core Earnings per share – outlook confirmed
border=Roche launches new immunoassay module for large volume laboratories
Roche announced today the launch of the cobas e 602 module for immunoassay testing as the latest addition to its cobas 8000 platform. This product is now available in Europe as well as in all countries recognizing the CE Mark in the Latin America and Asia-Pacific regions.
border=A New Study Shows that Testing for Human Papillomavirus Genotypes 16 and 18 Detects Cervical Pre-Cancer Missed by Pap Test
1 in 10 women in the ATHENA trial, age 30-years and older, who tested positive for HPV genotypes 16 and/or 18 by the cobas 4800 HPV Test had cervical pre-cancer, although their Pap test was normal. Involving more than 47,000 women, the ATHENA trial is the largest registration study ever conducted for cervical cancer screening.
border=Roche submits application to FDA for trastuzumab-DM1 in previously treated advanced HER2-positive breast cancer
Roche today announced that the company submitted a Biologics Licence Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.
border=Second phase III study showed Avastin-containing regimen helped women with ovarian cancer live longer without their disease getting worse
Roche announced today that a second large, phase III, international study showed that the combination of Avastin (bevacizumab) and chemotherapy followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone. Adverse events were consistent with those observed in pivotal trials of Avastin.
border=RoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis
Roche today announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that RoACTEMRA (known as ACTEMRA outside Europe) is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments.
border=Roche's MabThera is the first and only licensed biologic to offer a targeted B cell approach to rheumatoid arthritis (RA) treatment
Experts at this year's European League Against Rheumatism (EULAR) annual congress highlighted to rheumatologists that targeted treatment in RA, through the testing of specific blood markers at the time of diagnosis, could have a significant impact on treatment decisions, resulting in an improvement in patient quality of life.
border=All around the world: Roche Children's Walk to take place on International Day of the African Child
For many years, Roche employees at company sites around the world have been showing solidarity with children in need by supporting day-care centres in Malawi and children's charities in their own countries.
border=Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer live longer without their disease worsening
Roche today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.
top
See our Legal Statement
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.